Denali Therapeutics Inc.
DNLI- 交易所
- Nasdaq
- 產業
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
近 90 天,Denali Therapeutics Inc. 內部人申報 0 筆公開市場買進、3 筆賣出;2026 年第 3 季末有 286 家機構在 13F 申報持有,市值合計 $31.5 億;沒有大師持有。
持有 DNLI 5% 以上的大股東
最新一份 Schedule 13D 或 13G 申報持有 Denali Therapeutics Inc. 5% 以上的持有人,依持股比例由大到小;變化是跟這位持有人的上一份申報比。
| 持有人 | 最新表單 | 持股 | 變化 | 首次申報 | 最新申報 | 原文 |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 12.30%股數 1,963 萬 | +2.10 個百分點原本 10.20% | 2026/5/153 份 | 2026/11/16 | SEC |
| Baillie Gifford & Co | 13G/A | 7.50%股數 1,196 萬 | −1.10 個百分點原本 8.60% | 2021/1/126 份 | 2026/8/4 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%股數 1,049 萬 | – | 2024/10/213 份 | 2025/4/17 | SEC |
持股是每位持有人最新一份申報的數字。最後一份是舊格式(2024 年 12 月 18 日以前)的持有人沒有持股比例紀錄,不列在這裡;公司被收購或下市之後,持有人通常就不再申報。
13D 與 13G 申報
Denali Therapeutics Inc. 的 46 份 Schedule 13D、13G 申報,由新到舊,包括沒有持股比例的舊格式申報。
| 申報時間(美東) | 申報人 | 表單 | 持股 | 變化 | 事件日 | 原文 |
|---|---|---|---|---|---|---|
| 2026/11/1610:02 ET | T. Rowe Price Investment Management, Inc. | 13G/A | 12.30%股數 1,963 萬 | +2.10 個百分點原本 10.20% | 2026/9/30 | SEC |
| 2026/8/409:11 ET | Baillie Gifford & Co | 13G/A | 7.50%股數 1,196 萬 | −1.10 個百分點原本 8.60% | 2026/6/30 | SEC |
| 2026/7/811:30 ET | T. Rowe Price Investment Management, Inc. | 13G/A | 10.20%股數 1,618 萬 | +4.80 個百分點原本 5.40% | 2026/6/30 | SEC |
| 2026/5/1510:06 ET | T. Rowe Price Investment Management, Inc. | 13G | 5.40%股數 851.9 萬 | 新申報 | 2026/3/31 | SEC |
| 2026/5/611:13 ET | FMR LLC等 2 位 | 13G/A | 4.20%股數 667.3 萬 | −1.60 個百分點原本 5.80%低於 5% | 2026/3/31 | SEC |
| 2026/3/2618:06 ET | Vanguard Group Inc | 13G/A | 0.00%股數 0 | –低於 5% | 2026/3/13 | SEC |
| 2025/11/511:30 ET | FMR LLC等 2 位 | 13G/A | 5.80%股數 853.6 萬 | – | 2025/9/30 | SEC |
| 2025/8/1210:34 ET | Wellington Management Group LLP等 3 位 | 13G/A | 3.90%股數 566.5 萬 | –低於 5% | 2025/6/30 | SEC |
| 2025/4/1715:05 ET | BlackRock, Inc. | 13G/A | 7.20%股數 1,049 萬 | – | 2025/3/31 | SEC |
| 2025/2/1314:14 ET | Capital Research Global Investors | 13G/A | 3.80%股數 547.7 萬 | –低於 5% | 2024/12/31 | SEC |
| 2025/2/1210:52 ET | Baillie Gifford & Co | 13G/A | 8.60%股數 1,231 萬 | – | 2024/12/31 | SEC |
| 2024/11/12 | Capital Research Global Investors | 13G舊制 | – | 新申報 | – | SEC |
| 2024/11/12 | FMR LLC | 13G/A舊制 | – | – | – | SEC |
| 2024/11/8 | BlackRock, Inc. | 13G/A舊制 | – | – | – | SEC |
| 2024/11/8 | Wellington Management Group LLP | 13G/A舊制 | – | – | – | SEC |
| 2024/11/716:48 ET | Biogen Inc. | 13G/A舊制 | – | – | – | SEC |
| 2024/10/21 | BlackRock, Inc. | 13G/A舊制 | – | – | – | SEC |
| 2024/8/16 | FMR LLC | 13G舊制 | – | – | – | SEC |
| 2024/2/13 | Vanguard Group Inc | 13G/A舊制 | – | – | – | SEC |
| 2024/2/13 | Bratton Douglas K | 13G/A舊制 | – | – | – | SEC |
| 2024/2/1219:07 ET | Biogen Inc. | 13G/A舊制 | – | – | – | SEC |
| 2024/2/8 | Wellington Management Group LLP | 13G舊制 | – | 新申報 | – | SEC |
| 2024/1/30 | Temasek Holdings (Private) Ltd | 13G/A舊制 | – | – | – | SEC |
| 2024/1/30 | Baillie Gifford & Co | 13G/A舊制 | – | – | – | SEC |
| 2024/1/2516:59 ET | BlackRock Inc. | 13G/A舊制 | – | – | – | SEC |
| 2023/3/30 | Temasek Holdings (Private) Ltd | 13G舊制 | – | 新申報 | – | SEC |
| 2023/2/13 | Bratton Douglas K | 13G/A舊制 | – | – | – | SEC |
| 2023/2/9 | Vanguard Group Inc | 13G/A舊制 | – | – | – | SEC |
| 2023/2/9 | FMR LLC | 13G/A舊制 | – | – | – | SEC |
| 2023/1/3117:52 ET | BlackRock Inc. | 13G/A舊制 | – | – | – | SEC |
| 2023/1/20 | Baillie Gifford & Co | 13G/A舊制 | – | – | – | SEC |
| 2022/2/14 | Bratton Douglas K | 13G/A舊制 | – | – | – | SEC |
| 2022/2/14 | Price T Rowe Associates Inc | 13G/A舊制 | – | – | – | SEC |
| 2022/2/9 | Vanguard Group Inc | 13G/A舊制 | – | – | – | SEC |
| 2022/2/9 | FMR LLC | 13G/A舊制 | – | – | – | SEC |
| 2022/2/8 | ARCH Venture Fund VIII, L.P. | 13G/A舊制 | – | – | – | SEC |
| 2022/2/316:41 ET | BlackRock Inc. | 13G/A舊制 | – | – | – | SEC |
| 2022/1/18 | Baillie Gifford & Co | 13G/A舊制 | – | – | – | SEC |
| 2021/2/16 | Flagship Ventures Fund V, L.P. | 13G/A舊制 | – | – | – | SEC |
| 2021/2/16 | Price T Rowe Associates Inc | 13G舊制 | – | 新申報 | – | SEC |
| 2021/2/12 | Bratton Douglas K | 13G/A舊制 | – | – | – | SEC |
| 2021/2/10 | Vanguard Group Inc | 13G/A舊制 | – | – | – | SEC |
| 2021/2/8 | FMR LLC | 13G/A舊制 | – | – | – | SEC |
| 2021/2/214:56 ET | BlackRock Inc. | 13G舊制 | – | 新申報 | – | SEC |
| 2021/2/2 | ARCH Venture Fund VIII, L.P. | 13G/A舊制 | – | – | – | SEC |
| 2021/1/12 | Baillie Gifford & Co | 13G/A舊制 | – | – | – | SEC |
Form 144:內部人預計賣出
高階主管、董事與其他關係人預計賣出 Denali Therapeutics Inc. 股票的 78 份通知,由新到舊。
| 申報時間(美東) | 賣方 | 預計賣出股數 | 市值 | 預計賣出日 | 券商 | 原文 |
|---|---|---|---|---|---|---|
| 2026/9/420:38 ET | Chin Peter Scott高階主管 | 1,654 | $3.69 萬 | 2026/9/4 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/9/216:31 ET | Nancy Thornberry董事 | 1.14 萬 | $26.6 萬 | 2026/9/210b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/9/116:47 ET | Alexander Schuth高階主管 | 2,768 | $6.58 萬 | 2026/9/110b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/8/1117:39 ET | Schuth Alexander O.高階主管 | 2,857 | $7.16 萬 | 2026/8/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/2/516:14 ET | Carole Ho前關係人 | 3.95 萬 | $80.1 萬 | 2026/2/5 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/2/416:16 ET | Carole Ho前關係人 | 15.0 萬 | $317.7 萬 | 2026/2/4 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/2/316:47 ET | Carole Ho前關係人 | 15.0 萬 | $332.4 萬 | 2026/2/3 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/1/620:28 ET | Ho CaroleConsultant | 1.72 萬 | $28.4 萬 | 2026/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/1/620:25 ET | Schuth Alexander O.高階主管 | 1.72 萬 | $28.4 萬 | 2026/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2026/1/620:24 ET | Watts Ryan J.董事 · 高階主管 | 3.52 萬 | $58.1 萬 | 2026/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/12/416:41 ET | Carole Ho高階主管 | 1,882 | $3.58 萬 | 2025/12/410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/8/1316:45 ET | Carole Ho高階主管 | 806 | $1.07 萬 | 2025/8/1310b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/8/1220:46 ET | Schuth Alexander O.高階主管 | 2,937 | $3.99 萬 | 2025/8/12 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/8/1220:44 ET | Ho Carole高階主管 | 2,937 | $3.99 萬 | 2025/8/12 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/7/916:13 ET | Watts Ryan J.高階主管 | 49.5 萬 | $709.7 萬 | 2025/7/910b5-1 | Jefferies LLC | SEC |
| 2025/1/720:14 ET | Ho Carole高階主管 | 2,907 | $6.05 萬 | 2025/1/7 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:12 ET | Schuth Alexander O.高階主管 | 2,907 | $6.05 萬 | 2025/1/7 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:10 ET | Watts Ryan J.董事 · 高階主管 | 7,650 | $15.9 萬 | 2025/1/7 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:08 ET | Krognes Steve E.董事 | 3,339 | $6.95 萬 | 2025/1/7 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:06 ET | Schuth Alexander O.高階主管 | 1.23 萬 | $24.8 萬 | 2025/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:03 ET | Watts Ryan J.董事 · 高階主管 | 2.93 萬 | $59.2 萬 | 2025/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/720:01 ET | Ho Carole高階主管 | 1.23 萬 | $24.8 萬 | 2025/1/6 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2025/1/216:23 ET | Vicki Lee Sato董事 | 6,160 | $12.6 萬 | 2025/1/210b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2024/12/3116:17 ET | Steve Krognes董事 | 3.00 萬 | $60.7 萬 | 2024/12/3110b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| 2024/11/1207:47 ET | David Schenkein董事 | 5.94 萬 | $186.3 萬 | 2024/11/1110b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
只列最新的 25 份。看 DNLI 近 12 個月的全部通知